Trial Profile
Study on the Treatment of Refractory and Locally Advanced Head and Neck Malignant Tumor With Anlotinib Hydrochloride Capsules Combined With Chemoradiotherapy
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 05 Jan 2023
Price :
$35
*
At a glance
- Drugs Catequentinib (Primary)
- Indications Adenocarcinoma; Adenoid cystic carcinoma; Head and neck cancer; Sarcoma; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- 05 Aug 2020 Status changed from not yet recruiting to recruiting.
- 04 Aug 2020 New trial record